Market News

4 min read | Updated on November 18, 2026, 10:10 IST
SUMMARY
Biocon shares gained after the opening bell on November 18, after the pharmaceutical company secured approval to sell its breast cancer biosimilar drug in the European market. Here's what investors need to know.
Stock list

Biocon disclosed the Europe sales approval for its biosimilar breast cancer drug ahead of the market opening bell on Wednesday, November 18. | Image: Shutterstock
Pharmaceutical major Biocon shares gained during the morning hours on Wednesday, November 18, after the European Commission granted marketing approval to the company to sell its breast cancer biosimilar drug, Pebrilzo®, in the European Union.
NSE data showed that Biocon shares rose 1.08% to hit an early high of ₹363.30 apiece on Wednesday’s market, in comparison to ₹359.40 apiece at the previous equity market close.
The marketing approval allows any pharma company to legally sell and distribute its drugs in a specific market, in line with the health regulatory agency’s approval.
“Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach,” the company said in a press release.
This comes months after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the authorities grant marketing authorisation to Biocon’s pertuzumab biosimilar drug for the treatment of HER2‑positive breast cancer across multiple disease stages.
The CHMP is a scientific committee of the European Medicines Agency which is responsible for issuing opinions on human medicines after assessing the quality, safety, and efficacy of the drugs.
“With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer,” said Shreehas Tambe, CEO & Managing Director of Biocon.
Biosimilars are essentially medicines which are highly similar in composition to an already regulator-approved original biologic drug, which has been used as a reference to create other variants.
These biosimilar drugs are not identical copies of the original medicines, but have no clinically meaningful differences from the reference product. Thus, maintaining the same safety and effectiveness from the biosimilar over the course of treatment.
Companies produce biosimilar drugs because they cost significantly less than the original brand-name drug, in turn easing the price pressure on the patients while increasing revenues through higher sales.
Biocon’s Pebrilzo® drug is a biosimilar medicinal product to pertuzumab, and has been approved as a 420 mg concentrate for solution for infusion.
“A biosimilar medicinal product and the active substance is pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2,” said Biocon.
The Pebrilzo® drug will be used in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence, as well as in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
“In addition, it is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease,” the company said.
NSE data also showed that although Biocon shares have gained nearly 4% in the last one-month period, the stock has lost 1.4% in the last five market sessions. On a YTD basis, the stock has declined 6.4% so far this year.
In the longer term, Biocon shares have declined 1.1% in the last five years, but have delivered nearly 56% returns to investors in the last three years.
However, the stock has lost 14% in the last one-year period, according to the exchange data.
The company’s market capitalisation (m-cap) was at ₹59,076 crore as of the trading session on Wednesday, November 18.
Related News
About The Author

Next Story